NORTH CHICAGO, Ill., Sept. 13, 2018 /PRNewswire/ — AbbVie (NYSE:
Read more
miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
BOULDER, Colo., July 10, 2018 (GLOBE NEWSWIRE) — miRagen Therapeutics,
Read moreAclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
WAYNE, Pa., June 28, 2018 (GLOBE NEWSWIRE) — Aclaris Therapeutics,
Read more